Cardiovascular Outcomes in Aortopathy: GenTAC Registry of Genetically Triggered Aortic Aneurysms and Related Conditions.
Loeys-Dietz
Marfan
Turner
aortic aneurysm
aortic dissection
bicuspid aortic valve
nonsyndromic heritable aortic disease
vascular Ehlers-Danlos
Journal
Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365
Informations de publication
Date de publication:
31 05 2022
31 05 2022
Historique:
received:
01
02
2022
revised:
14
03
2022
accepted:
15
03
2022
entrez:
26
5
2022
pubmed:
27
5
2022
medline:
31
5
2022
Statut:
ppublish
Résumé
The GenTAC (Genetically Triggered Thoracic Aortic Aneurysm and Cardiovascular Conditions) Registry enrolled patients with genetic aortopathies between 2007 and 2016. The purpose of this study was to compare age distribution and probability of elective surgery for proximal aortic aneurysm, any dissection surgery, and cardiovascular mortality among aortopathy etiologies. The GenTAC study had a retrospective/prospective design. Participants with bicuspid aortic valve (BAV) with aneurysm (n = 879), Marfan syndrome (MFS) (n = 861), nonsyndromic heritable thoracic aortic disease (nsHTAD) (n = 378), Turner syndrome (TS) (n = 298), vascular Ehlers-Danlos syndrome (vEDS) (n = 149), and Loeys-Dietz syndrome (LDS) (n = 121) were analyzed. The 25% probability of elective proximal aortic aneurysm surgery was 30 years for LDS (95% CI: 18-37 years), followed by MFS (34 years; 95% CI: 32-36 years), nsHTAD (52 years; 95% CI: 48-56 years), and BAV (55 years; 95% CI: 53-58 years). Any dissection surgery 25% probability was highest in LDS (38 years; 95% CI: 33-53 years) followed by MFS (51 years; 95% CI: 46-57 years) and nsHTAD (54 years; 95% CI: 51-61 years). BAV experienced the largest relative frequency of elective surgery to any dissection surgery (254/33 = 7.7), compared with MFS (273/112 = 2.4), LDS (35/16 = 2.2), or nsHTAD (82/76 = 1.1). With MFS as the reference population, risk of any dissection surgery or cardiovascular mortality was lowest in BAV patients (HR: 0.13; 95% CI: 0.08-0.18; HR: 0.13; 95%: CI: 0.06-0.27, respectively). The greatest risk of mortality was seen in patients with vEDS. Marfan and LDS cohorts demonstrate age and event profiles congruent with the current understanding of syndromic aortopathies. BAV events weigh toward elective replacement with relatively few dissection surgeries. Nonsyndromic HTAD patients experience near equal probability of dissection vs prophylactic surgery, possibly because of failure of early diagnosis.
Sections du résumé
BACKGROUND
The GenTAC (Genetically Triggered Thoracic Aortic Aneurysm and Cardiovascular Conditions) Registry enrolled patients with genetic aortopathies between 2007 and 2016.
OBJECTIVES
The purpose of this study was to compare age distribution and probability of elective surgery for proximal aortic aneurysm, any dissection surgery, and cardiovascular mortality among aortopathy etiologies.
METHODS
The GenTAC study had a retrospective/prospective design. Participants with bicuspid aortic valve (BAV) with aneurysm (n = 879), Marfan syndrome (MFS) (n = 861), nonsyndromic heritable thoracic aortic disease (nsHTAD) (n = 378), Turner syndrome (TS) (n = 298), vascular Ehlers-Danlos syndrome (vEDS) (n = 149), and Loeys-Dietz syndrome (LDS) (n = 121) were analyzed.
RESULTS
The 25% probability of elective proximal aortic aneurysm surgery was 30 years for LDS (95% CI: 18-37 years), followed by MFS (34 years; 95% CI: 32-36 years), nsHTAD (52 years; 95% CI: 48-56 years), and BAV (55 years; 95% CI: 53-58 years). Any dissection surgery 25% probability was highest in LDS (38 years; 95% CI: 33-53 years) followed by MFS (51 years; 95% CI: 46-57 years) and nsHTAD (54 years; 95% CI: 51-61 years). BAV experienced the largest relative frequency of elective surgery to any dissection surgery (254/33 = 7.7), compared with MFS (273/112 = 2.4), LDS (35/16 = 2.2), or nsHTAD (82/76 = 1.1). With MFS as the reference population, risk of any dissection surgery or cardiovascular mortality was lowest in BAV patients (HR: 0.13; 95% CI: 0.08-0.18; HR: 0.13; 95%: CI: 0.06-0.27, respectively). The greatest risk of mortality was seen in patients with vEDS.
CONCLUSIONS
Marfan and LDS cohorts demonstrate age and event profiles congruent with the current understanding of syndromic aortopathies. BAV events weigh toward elective replacement with relatively few dissection surgeries. Nonsyndromic HTAD patients experience near equal probability of dissection vs prophylactic surgery, possibly because of failure of early diagnosis.
Identifiants
pubmed: 35618343
pii: S0735-1097(22)04632-0
doi: 10.1016/j.jacc.2022.03.367
pmc: PMC9205611
mid: NIHMS1795110
pii:
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2069-2081Subventions
Organisme : NHLBI NIH HHS
ID : HHSN268200648199C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201000048C
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002369
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Funding Support and Author Disclosures The GenTAC (Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions) Registry has been supported by U.S. Federal Government contracts HHSN268200648199C and HHSN268201000048C from the National Heart, Lung, and Blood Institute and the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Dr LeMaire has served as a consultant for Terumo Aortic and Cerus; and has served as a principal investigator for clinical studies sponsored by Terumo Aortic and CytoSorbents. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Références
Genet Med. 2019 Aug;21(8):1683-1690
pubmed: 30573797
Am Heart J. 2009 Feb;157(2):319-26
pubmed: 19185640
Medicine (Baltimore). 2012 Nov;91(6):287-308
pubmed: 23117850
Eur J Cardiothorac Surg. 2016 Dec;50(6):1111-1117
pubmed: 27334108
PLoS Genet. 2018 Oct 3;14(10):e1007692
pubmed: 30281655
J Thorac Cardiovasc Surg. 2020 Jun;159(6):2216-2226.e2
pubmed: 31543305
Ann Thorac Surg. 2009 Sep;88(3):781-7; discussion 787-8
pubmed: 19699898
J Am Coll Cardiol. 2021 Feb 2;77(4):450-500
pubmed: 33342587
J Am Coll Cardiol. 2010 Jun 22;55(25):2789-800
pubmed: 20579534
N Engl J Med. 2006 Aug 24;355(8):788-98
pubmed: 16928994
J Am Coll Cardiol. 2018 Aug 7;72(6):605-615
pubmed: 30071989
Circ Cardiovasc Genet. 2016 Dec;9(6):548-558
pubmed: 27879313
Am Heart J. 2011 Oct;162(4):627-632.e1
pubmed: 21982653
PLoS One. 2019 Mar 18;14(3):e0214084
pubmed: 30883599
Ann Thorac Surg. 2020 May;109(5):1378-1384
pubmed: 31568749
J Thorac Cardiovasc Surg. 2022 Jan;163(1):39-45
pubmed: 33648726
J Am Coll Cardiol. 2010 Apr 6;55(14):e27-e129
pubmed: 20359588
Surg Clin North Am. 1966 Aug;46(4):1045-55
pubmed: 6003090
Genet Med. 2021 Jan;23(1):111-122
pubmed: 32855533
JACC Cardiovasc Imaging. 2016 Mar;9(3):219-26
pubmed: 26897684
PLoS One. 2016 Apr 19;11(4):e0153543
pubmed: 27092555
J Am Coll Cardiol. 2016 Jun 14;67(23):2744-2754
pubmed: 27282895
Ann Thorac Surg. 2020 Feb;109(2):534-540
pubmed: 31376376
Am J Med Genet C Semin Med Genet. 2019 Mar;181(1):117-125
pubmed: 30770620
J Med Genet. 2009 Sep;46(9):607-13
pubmed: 19542084
Am J Med Genet A. 2013 Apr;161A(4):779-86
pubmed: 23444191
Nat Rev Cardiol. 2011 Feb;8(2):103-13
pubmed: 21173794